Sector News

Eli Lilly set to acquire Dermira, including lebrikizumab

January 14, 2020
Life sciences

Eli Lilly has announced plans to buy Dermira for around $1.1 billion, expanding its immunology pipeline in the process.

As part of the agreement Lilly will add lebrikizumab, Dermira’s moderate-to-severe atopic dermatitis drug currently at Phase III stage, to its pipeline.

Under the terms of the deal, Lilly says that it will commence a tender offer to acquire all outstanding shares of the biopharmaceutical company for a purchase price of $18.75 per share in cash.

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of atopic dermatitis.

Patients with moderate-to-severe atopic dermatitis have “significant unmet treatment needs,” reminded Patrik Jonsson, Lilly senior vice president, before going on to say the company is “excited about the potential that lebrikizumab has to help these patients.

Patrik continued, “The acquisition of Dermira is consistent with Lilly’s strategy to augment our own internal research by acquiring clinical phase assets in our core therapeutic areas and leveraging our development expertise and commercial infrastructure to bring new medicines to patients.

“This acquisition provides an opportunity to add a promising Phase III immunology compound for atopic dermatitis, while also adding an approved dermatology treatment for primary axillary hyperhidrosis. We look forward to completing the acquisition and continuing Dermira’s excellent work.”

The drug was granted Fast Track designation from the US Food and Drug Administration (FDA) in December 2019, after being out-licensed from Roche to Dermira in 2017.

By Anna Smith

Source: Pharma Times

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).